Advertisement
Screener

LEMAITRE VASCULAR, INC. (LMAT) Amortization of Debt Issuance Costs

2.8 / 5 stars · 68/120 Roast Me

LEMAITRE VASCULAR, INC. Amortization of Debt Issuance Costs

LEMAITRE VASCULAR, INC. (LMAT) reported Amortization of Debt Issuance Costs of $446.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-05

  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $224.00K, a 1.36% increase year-over-year.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $222.00K, a 4.72% increase year-over-year.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $220.00K, a 254.84% increase year-over-year.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $220.00K.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for fiscal 2025 was $873.00K, a 1308.06% increase from fiscal 2024.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for fiscal 2024 was $62.00K.
  • LEMAITRE VASCULAR, INC. amortization of debt issuance costs for fiscal 2023 was $0.00.
Period endAmortization of Debt Issuance Costs 3 monthAmortization of Debt Issuance Costs 6 monthAmortization of Debt Issuance Costs 9 monthAmortization of Debt Issuance Costs 12 month
2026-06-30$224.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$446.00K
10-Q · filed 2026-08-05
$666.00K
derived: sum of 3 quarters · filed 2026-08-05
$886.00K
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$222.00K
10-Q · filed 2026-05-06
$442.00K
derived: sum of 2 quarters · filed 2026-05-06
$662.00K
derived: sum of 3 quarters · filed 2026-05-06
$883.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$220.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$440.00K
derived: sum of 2 quarters · filed 2026-02-26
$661.00K
derived: sum of 3 quarters · filed 2026-08-05
$873.00K
10-K · filed 2026-02-26
2025-09-30$220.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
$441.00K
derived: sum of 2 quarters · filed 2026-08-05
$653.00K
10-Q · filed 2025-11-07
$715.00K
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$221.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$433.00K
10-Q · filed 2026-08-05
$495.00K
derived: sum of 3 quarters · filed 2026-08-05
2025-03-31$212.00K
10-Q · filed 2026-05-06
$274.00K
derived: sum of 2 quarters · filed 2026-05-06
2024-12-31$62.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$62.00K
10-K · filed 2026-02-26
2024-09-30$0.00
10-Q · filed 2025-11-07
2023-12-31$0.00
10-K · filed 2026-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
NovoCure Ltd (NVCR)$1.886B-11.87
Inspire Medical Systems, Inc. (INSP)United States$1.990B9.55
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
UFP TECHNOLOGIES INC (UFPT)United States$2.308B28.37
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77